Skip to main content Accessibility help
×
Home

When health technology assessment is confidential and experts have no power: the case of Hungary

  • Marcell Csanádi (a1), Olga Löblová (a2), Piotr Ozierański (a3), András Harsányi (a4) (a5), Zoltán Kaló (a4), Martin McKee (a6) and Lawrence King (a7)...

Abstract

Health technology assessment (HTA) is not simply a mechanistic technical exercise as it takes place within a specific institutional context. Yet, we know little about how this context influences the operation of HTA and its ability to influence policy and practice. We seek to demonstrate the importance of considering institutional context, using a case study of Hungary, a country that has pioneered HTA in Central and Eastern Europe. We conducted 26 in-depth, semi-structured interviews with public- and private-sector stakeholders. We found that while the HTA Department, the Hungarian HTA organisation, fulfilled its formal role envisaged in the legislation, its potential for supporting evidence-based decision-making was not fully realised given the low levels of transparency and stakeholder engagement. Further, the Department’s practical influence throughout the reimbursement process was perceived as being constrained by the payer and policy-makers, as well as its own limited organisational capacity. There was also scepticism as to whether the current operational form of the HTA process delivered ‘good value for money’. Nevertheless, it still had a positive impact on the development of a broader institutional HTA infrastructure in Hungary. Our findings highlight the importance of considering institutional context in analysing the HTA function within health systems.

Copyright

Corresponding author

*Correspondence to: Marcell Csanádi, PhD student, Doctoral School of Pharmacological and Pharmaceutical Sciences, University of Pécs, 7624 Pécs, Honvéd u. 3, Hungary. Email: marcell.csanadi@syreon.eu

References

Hide All
Banta, D. (2003), ‘The development of health technology assessment’, Health Policy, 63: 121132.
Berntgen, M., Gourvil, A., Pavlovic, M., Goettsch, W., Eichler, H. G. and Kristensen, F. B. (2014), ‘Improving the contribution of regulatory assessment reports to health technology assessments – a collaboration between the European Medicines Agency and the European network for Health Technology Assessment’, Value in Health, 17: 634641.
Bochenek, T., Kocot, E., Rodzinka, M., Godman, B., Maciejewska, K., Kamal, S. and Pilc, A. (2017), ‘The transparency of published health technology assessment-based recommendations on pharmaceutical reimbursement in Poland’, Expert Review of Pharmacoeconomics & Outcomes Research, 17(4): 385400.
Böhm, K., Landwehr, C. and Steiner, N. (2014), ‘What explains “generosity” in the public financing of high-tech drugs? An empirical investigation of 25 OECD countries and 11 controversial drugs’, Journal of European Social Policy, 24: 3955.
Boncz, I., Dozsa, C., Kalo, Z., Nagy, L., Borcsek, B., Brandtmuller, A., Betlehem, J., Sebestyen, A. and Gulacsi, L. (2006), ‘Development of health economics in Hungary between 1990-2006’, European Journal of Health Economics, 7(Supplement 1): 46.
Endrei, D., Molics, B. and Agoston, I. (2014), ‘Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary’, Value in Health, 17: 487489.
Fischer, K. E., Rogowski, W. H., Leidl, R. and Stollenwerk, B. (2013), ‘Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis’, Health Policy, 112: 187196.
Guest, G. S., MacQueen, K. M. and Namey, E. E. (2011), Applied Thematic Analysis, Thousand Oaks, CA: SAGE Publications.
Gulácsi, L. and Pentek, M. (2014), ‘HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain’, European Journal of Health Economics, 15: 675680.
Gulacsi, L., Boncz, I. and Drummond, M. (2004), ‘Issues for countries considering introducing the “fourth hurdle”: the case of Hungary’, International Journal of Technology Assessment in Health Care, 20(3): 337341.
Gulácsi, L., Brodszky, V., Pentek, M., Varga, S., Vas, G. and Boncz, I. (2009), ‘History of health technology assessment in Hungary’, International Journal of Technology Assessment in Health Care, 25(Supplement 1): 120126.
Gulácsi, L., Rotar, A. M., Niewada, M., Löblová, O., Rencz, F., Petrova, G., Boncz, I. and Klazinga, N. S. (2014), ‘Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria’, European Journal of Health Economics, 15(Supplement 1): S13S25.
Henshall, C., Oortwijn, W., Stevens, A., Granados, A. and Banta, D. (1997), ‘Priority setting for health technology assessment. Theoretical considerations and practical approaches. Priority setting subgroup of the EUR-ASSESS Project’, International Journal of Technology Assessment in Health Care, 13: 144185.
Huic, M., Tandara Hacek, R. and Svajger, I. (2017), ‘Health technology assessment in Central, Eastern and South European countries: Croatia’, International Journal of Technology Assessment in Health Care, 33(3): 376383.
Inotai, A., Pekli, M., Jona, G., Nagy, O., Remak, E. and Kaló, Z. (2012), ‘Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology’, BMC Health Services Research, 12: 332.
Jacob, R. and McGregor, M. (1997), ‘Assessing the impact of health technology assessment’, International Journal of Technology Assessment in Health Care, 13: 6880.
Kaló, Z., Gheorghe, A., Huic, M., Csanadi, M. and Kristensen, F. B. (2016), ‘HTA implementation roadmap in Central and Eastern European countries’, Health Economics, 25(Supplement 1): 179192.
Kaló, Z., Bodrogi, J., Boncz, I., Dózsa, C., Jóna, G., Kövi, R., Pásztélyi, Z. and Sinkovits, B. (2013), ‘Capacity building for HTA implementation in middle-income countries: the case of Hungary’, Value in Health Regional Issues, 2: 264266.
Kani, C., Kourafalos, V. and Litsa, P. (2017), ‘Current environment for introducing health technology assessment in Greece’, International Journal of Technology Assessment in Health Care, 33(3): 396401.
Kawalec, P. and Malinowski, K. P. (2016), ‘Relating health technology assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis’, Health Policy, 120(11): 12401248.
Kolasa, K., Dziomdziora, M. and Fajutrao, L. (2011a), ‘What aspects of the health technology assessment process recommended by international health technology assessment agencies received the most attention in Poland in 2008?’, International Journal of Technology Assessment in Health Care, 27: 8494.
Kolasa, K., Kaló, Z. and Zah, V. (2016), ‘The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations’, Expert Review of Pharmacoeconomics & Outcomes Research, 16: 483488.
Kolasa, K., Schubert, S., Manca, A. and Hermanowski, T. (2011b), ‘A review of health technology assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland’, Health Policy, 102: 145151.
Kolasa, K., Kaló, Z., Zah, V. and Dolezal, T. (2012), ‘Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries’, Expert Review of Pharmacoeconomics & Outcomes Research, 12: 283287.
Landwehr, C. and Boehm, K. (2011), ‘Delegation and institutional design in health-care rationing’, Governance, 24: 665688.
Lavín, C. P., Alaniz, R. and Espinoza, M. (2017), ‘Visions of stakeholders about instutionalization of health technology assessment in Chile: a qualitative study’, International Journal of Technology Assessment in Health Care, 33(2): 303306.
Löblová, O. (2016), ‘Three worlds of health technology assessment: explaining patterns of diffusion of HTA agencies in Europe’, Health Economics, Policy and Law, 11(3): 253273.
Löblová, O. (2017a), ‘What has health technology assessment ever done for us?’, Journal of Health Services Research & Policy, doi: 10.1177/1355819617725545.
Löblová, O. (2017b), ‘Who’s afraid of institutionalizing health technology assessment (HTA)?: interests and policy positions on HTA in the Czech Republic’, Health Economics, Policy and Law, 13(2): 137161.
Mandrik, O., Knies, S., Kaló, Z. and Severens, J. L. (2015), ‘Reviewing transferability in economic evaluations originating from Eastern Europe’, International Journal of Technology Assessment in Health Care, 31: 434441.
Németh, B., Csanádi, M. and Kaló, Z. (2017), ‘Overview on the current implementation of health technology assessment in the healthcare system in Hungary’, International Journal of Technology Assessment in Health Care, 33(3): 333338.
Oortwijn, W. J., Hanney, S. R., Ligtvoet, A., Hoorens, S., Wooding, S., Grant, J., Buxton, M. J. and Bouter, L. M. (2008), ‘Assessing the impact of health technology assessment in the Netherlands’, International Journal of Technology Assessment in Health Care, 24: 259269.
Ozieranski, P. and King, L. (2016), ‘The persistence of cliques in the post-communist state. The case of deniability in drug reimbursement policy in Poland’, British Journal of Sociology, 67: 216241.
Ozieranski, P. and King, L. (2017), ‘Governing drug reimbursement policy in Poland: the role of the state, civil society and the private sector’, Theory and Society, 46(6): 577610.
Ozieranski, P., McKee, M. and King, L. (2012a), ‘Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?’, Health Economics, Policy and Law, 7: 175195.
Ozieranski, P., McKee, M. and King, L. (2012b), ‘The politics of health technology assessment in Poland’, Health Policy, 108: 178193.
Rupel, P. V. (2017), ‘Current implementation of health technology assessment in healthcare system in Slovenia’, International Journal of Technology Assessment in Health Care, 33(3): 360364.
Schumacher, I. and Zechmeister, I. (2013), ‘Assessing the impact of health technology assessment on the Austrian healthcare system’, International Journal of Technology Assessment in Health Care, 29: 8491.
Szende, Á., Mogyorósy, Z., Muszbek, N., Nagy, J., Pallos, G. and Dózsa, C. (2002), ‘Methodological guidelines for conducting economic evaluation of healthcare interventions in Hungary: a Hungarian proposal for methodology standards’, The European Journal of Health Economics, 3: 196206.
Valesco-Garrido, M. and Busse, R. (2005), Health Technology Assessment – An Introduction to Objectives, Role of Evidence, and Structure in Europe, European Observatory on Health Systems and Policies, Copenhagen, Denmark.
Voko, Z., Cheung, K. L., Jozwiak-Hagymasy, J., Wolfenstetter, S., Jones, T., Munoz, C., Evers, S. M., Hiligsmann, M., de Vries, H. and Pokhrel, S. (2016), ‘Similarities and differences between stakeholders’ opinions on using health technology assessment (HTA) information across five European countries: results from the EQUIPT survey’, Health Research Policy and Systems, 14: 38.
Yin, R. K. (2003), Case Study Research: Design and Methods: Volume 5 (Applied Social Research Methods), Thousand Oaks, CA: SAGE Publications.
Zechmeister, I. and Schumacher, I. (2012), ‘The impact of health technology assessment reports on decision making in Austria’, International Journal of Technology Assessment in Health Care, 28: 7784.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed